TY - JOUR
T1 - Disruption of synaptosomal calcium channel function by Lambert-Eaton myasthenic immunoglobulin is serum-dependent
AU - Hewett, Sandra J.
AU - Atchison, William D.
N1 - Funding Information:
AcknowledgementTsh. e authors thank Becky Heydecke,A nnette McLane, Nancy Mummaw and Sharon Christensenfo r technical assistancaen dG retchenH umphriesa ntiKim lsaacsonfo r secretarial assistanceS.p ecialt hankst o Dr. J.B. Suszkiw+U niversityo f Cincinnati, tor helpful discussionsW. e acknowledgteh e generousg iftsof LEMS sera/plasmfar om Dr. Mark GlasbergH, enryFord Hospital Detroit,M I. This paperw as submittebdy S.J.H. in partialf ulfillment of the requirementfso r the Ph.D. degree in Pharmacologya nd Toxicologya t Michigan State University.W .D.A. is a recipiento f ResearchC areerD evelopmenAtw ard 5K04-ES00178T.h is work was supportedb y the Muscular DystrophyA ssociationa nd in part by NIH Grant ES05820.
PY - 1992/12/25
Y1 - 1992/12/25
N2 - An autoantibody to nerve terminal Ca2+ channels has been suggested to mediate the pathogenesis of the neuromuscular disorder Lambert-Eaton Myasthenic Syndrome (LEMS). We demonstrated previously that in the presence of control human serum, immunoglobulins isolated from a patient with LEMS reduced flux of Ca2+ into isolated nerve terminals during depolarization. The objective of the present study was to determine the role of serum in reducing uptake of 45Ca2+ into rat brain synaptosomes by LEMS IgG. Depolarization-dependent uptake of 45Ca2+ through voltage-gated Ca2+ channels was determined using synaptosomes incubated with control (disease-free) and LEMS IgG with or without control human serum. In the absence of human serum, LEMS IgG did not reduce uptake of 45Ca2+ into synaptosomes. However, in the presence of control human serum (10% of total incubation volume), 45Ca2+ uptake was reduced significantly by LEMS IgG (2 and 4 mg/ml), but not by IgG from disease-free patients or by 10% (v/v) control human serum alone. This concentration of serum was found to be optimal; higher concentrations produced significant reductions in Ca2+ uptake, whereas at lower concentrations the serum/IgG combination was ineffective. The depressant effect of high concentrations of serum alone on 45Ca2+ uptake was mimicked by equal concentrations of bovine serum albumin suggesting that deficits in 45Ca2+ uptake produced by high concentrations of serum were due to increased protein binding of the radiolabel. Heat-inactivating the serum abolished its ability to interact with the LEMS immunoglobulins to depress 45Ca2+ uptake. This suggested a role for complement in this effect. To test whether the membrane attack complex (MAC) or the alternative pathway of complement (APC) contributed to the alteration in Ca2+ channel function, 45Ca2+ uptake into synaptosomes was measured following incubation with LEMS IgG and C5- or Factor B-deficient serum, respectively. LEMS IgG reduced K+-stimulated uptake in both cases. Thus, neither the MAC nor the APC contributed to disruption of Ca2+ channel function by LEMS IgG in synaptosomes. In contrast, incubation of synaptosomes with LEMS IgG and C3-deficient serum prevented the reduction in 45Ca2+ uptake suggesting that the C3 component of the complement pathway may participate in Ca2+ channel dysfunction in synaptosomes following incubation with serum and LEMS IgG.
AB - An autoantibody to nerve terminal Ca2+ channels has been suggested to mediate the pathogenesis of the neuromuscular disorder Lambert-Eaton Myasthenic Syndrome (LEMS). We demonstrated previously that in the presence of control human serum, immunoglobulins isolated from a patient with LEMS reduced flux of Ca2+ into isolated nerve terminals during depolarization. The objective of the present study was to determine the role of serum in reducing uptake of 45Ca2+ into rat brain synaptosomes by LEMS IgG. Depolarization-dependent uptake of 45Ca2+ through voltage-gated Ca2+ channels was determined using synaptosomes incubated with control (disease-free) and LEMS IgG with or without control human serum. In the absence of human serum, LEMS IgG did not reduce uptake of 45Ca2+ into synaptosomes. However, in the presence of control human serum (10% of total incubation volume), 45Ca2+ uptake was reduced significantly by LEMS IgG (2 and 4 mg/ml), but not by IgG from disease-free patients or by 10% (v/v) control human serum alone. This concentration of serum was found to be optimal; higher concentrations produced significant reductions in Ca2+ uptake, whereas at lower concentrations the serum/IgG combination was ineffective. The depressant effect of high concentrations of serum alone on 45Ca2+ uptake was mimicked by equal concentrations of bovine serum albumin suggesting that deficits in 45Ca2+ uptake produced by high concentrations of serum were due to increased protein binding of the radiolabel. Heat-inactivating the serum abolished its ability to interact with the LEMS immunoglobulins to depress 45Ca2+ uptake. This suggested a role for complement in this effect. To test whether the membrane attack complex (MAC) or the alternative pathway of complement (APC) contributed to the alteration in Ca2+ channel function, 45Ca2+ uptake into synaptosomes was measured following incubation with LEMS IgG and C5- or Factor B-deficient serum, respectively. LEMS IgG reduced K+-stimulated uptake in both cases. Thus, neither the MAC nor the APC contributed to disruption of Ca2+ channel function by LEMS IgG in synaptosomes. In contrast, incubation of synaptosomes with LEMS IgG and C3-deficient serum prevented the reduction in 45Ca2+ uptake suggesting that the C3 component of the complement pathway may participate in Ca2+ channel dysfunction in synaptosomes following incubation with serum and LEMS IgG.
KW - Calcium channel
KW - Complement
KW - Lambert-Eaton Myasthenic Syndrome
KW - Neuromuscular disorder
KW - Neurotransmitter release
KW - Synaptosome
UR - http://www.scopus.com/inward/record.url?scp=0027055131&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027055131&partnerID=8YFLogxK
U2 - 10.1016/0006-8993(92)90407-Z
DO - 10.1016/0006-8993(92)90407-Z
M3 - Article
C2 - 1363288
AN - SCOPUS:0027055131
SN - 0006-8993
VL - 599
SP - 317
EP - 323
JO - Brain Research
JF - Brain Research
IS - 2
ER -